Olmesartan-Induced Enteropathy

Abimbola Adike, Juan Corral, David Rybnicek, Daniel Sussman, Samir Shah, Eamonn Quigley

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Olmesartan-induced enteropathy mimics celiac disease clinically and pathologically. As in celiac disease, the pathologic findings are villous atrophy and increased intraepithelial lymphocytes. Clinical presentation of olmesartan-induced enteropathy includes diarrhea, weight loss, and nausea. In contrast to celiac disease, tissue transglutaminase is not elevated and there is no response to a gluten-free diet. Including this entity in the differential diagnosis of sprue-like enteropathy is critical for its early diagnosis since replacing olmesartan with an alternative antihypertensive drug can simplify the diagnostic workup and provide both clinical and histologic improvement.

Original languageEnglish (US)
Pages (from-to)230-232
Number of pages3
JournalMethodist DeBakey cardiovascular journal
Volume12
Issue number4
DOIs
StatePublished - Oct 1 2016

Keywords

  • celiac disease
  • diarrhea
  • olmesartan-induced enteropathy

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Olmesartan-Induced Enteropathy'. Together they form a unique fingerprint.

  • Cite this

    Adike, A., Corral, J., Rybnicek, D., Sussman, D., Shah, S., & Quigley, E. (2016). Olmesartan-Induced Enteropathy. Methodist DeBakey cardiovascular journal, 12(4), 230-232. https://doi.org/10.14797/mdcj-12-4-230